BRIEF published on 12/23/2024 at 21:09, 1 year 6 months ago Succès de l'offre publique de TME Pharma N.V. Actionnaires Augmentation De Capital Cancer NOX-A12 Stratégies Financières
BRIEF published on 12/23/2024 at 21:09, 1 year 6 months ago Successful public offering of TME Pharma NV Shareholders Capital Increase Cancer Financial Strategies NOX-A12
PRESS RELEASE published on 12/23/2024 at 21:04, 1 year 6 months ago Informations privilégiées / Autres communiqués TME Pharma réussit son offre publique de 2,6 millions d'euros, renforçant sa position financière jusqu'en juin 2025. Les actionnaires soutiennent la levée de fonds pour NOX-A12 et NOX-E36 Augmentation De Capital Offre Publique TME Pharma NOX-A12 NOX-E36
BRIEF published on 12/04/2024 at 19:55, 1 year 6 months ago TME Pharma annonce une mise à jour stratégique et un plan de financement de 2,6 millions d'euros Stratégie D'entreprise Offre Publique Plan De Financement Développement Du NOX-A12 Priorité Aux Actionnaires
BRIEF published on 12/04/2024 at 19:55, 1 year 6 months ago TME Pharma Announces Strategic Update and €2.6 Million Financing Plan Public Offer Corporate Strategy Financing Plan NOX-A12 Development Shareholder Priority
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 6 months ago Informations privilégiées / Autres communiqués TME Pharma annonce une nouvelle stratégie et un financement garanti de 2,6 millions d'euros pour ses projets NOX-A12 et NOX-E36 jusqu'en juin 2025 Financement Offre Publique TME Pharma NOX-A12 NOX-E36
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 6 months ago Inside Information / Other news releases TME Pharma announces corporate strategy update with upcoming €2.6 million financing aimed at further developing therapies for cancer treatment through public offer open to shareholders. CEO Mangasarian highlights strategic goals and plans Financing Cancer Treatment Public Offer Corporate Strategy TME Pharma
BRIEF published on 11/23/2024 at 10:59, 1 year 7 months ago TME Pharma présente ses résultats sur NOX-A12 dans le glioblastome Thérapie Contre Le Cancer Glioblastome NOX-A12 Inhibition Du Point De Contrôle Immunitaire Microenvironnement Tumoral
BRIEF published on 11/23/2024 at 10:59, 1 year 7 months ago TME Pharma Presents Findings on NOX-A12 in Glioblastoma Cancer Therapy Glioblastoma NOX-A12 Immune Checkpoint Inhibition Tumor Microenvironment
PRESS RELEASE published on 11/23/2024 at 10:54, 1 year 7 months ago Informations privilégiées / Autres communiqués TME Pharma annonce la présentation d'un poster par le National Cancer Institute américain sur l'inhibition de CXCL12 par NOX-A12 dans le glioblastome à la réunion annuelle du SNO 2024 Glioblastome TME Pharma NOX-A12 National Cancer Institute Inhibition
Published on 06/27/2026 at 16:50, 9 hours 45 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 2 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 3 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 3 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 1 day 2 hours ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 2 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 2 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 2 hours ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day 3 hours ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
